Point72 DIFC Ltd Buys Shares of 17,143 Verve Therapeutics, Inc. (NASDAQ:VERV)

Point72 DIFC Ltd bought a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERVFree Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 17,143 shares of the company’s stock, valued at approximately $83,000.

A number of other institutional investors and hedge funds also recently modified their holdings of VERV. Price T Rowe Associates Inc. MD grew its holdings in Verve Therapeutics by 28.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 25,366 shares of the company’s stock valued at $337,000 after purchasing an additional 5,600 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Verve Therapeutics by 908.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock valued at $38,000 after buying an additional 6,949 shares during the period. Accredited Investors Inc. increased its position in shares of Verve Therapeutics by 16.3% in the 2nd quarter. Accredited Investors Inc. now owns 17,500 shares of the company’s stock valued at $85,000 after buying an additional 2,455 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Verve Therapeutics by 22.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,873 shares of the company’s stock worth $1,341,000 after buying an additional 49,922 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Verve Therapeutics by 12.2% during the second quarter. Rhumbline Advisers now owns 112,446 shares of the company’s stock worth $549,000 after acquiring an additional 12,199 shares in the last quarter. 97.11% of the stock is owned by institutional investors.

Verve Therapeutics Price Performance

VERV stock opened at $6.47 on Monday. The stock has a market capitalization of $547.75 million, a P/E ratio of -2.63 and a beta of 1.71. Verve Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $19.34. The business has a 50-day moving average of $5.55 and a 200-day moving average of $5.61.

Verve Therapeutics (NASDAQ:VERVGet Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The firm had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business’s revenue was up 120.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.72) EPS. Equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on VERV. HC Wainwright lowered their price target on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group raised their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th.

Get Our Latest Report on VERV

About Verve Therapeutics

(Free Report)

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

Read More

Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERVFree Report).

Institutional Ownership by Quarter for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.